Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa)

Cancer Research

Volumn 62, Issue 15, 2002, Pages 4300-4306

  Huang, Shyh Min ^a   Li, Jing ^a   Armstrong, Eric A ^a   Harari, Paul M ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CAPILLARY PROLIFERATION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; FLOW CYTOMETRY; GENE AMPLIFICATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; RADIATION RESPONSE; SQUAMOUS CELL CARCINOMA; TUMOR REGRESSION; UMBILICAL CORD; VASCULAR ENDOTHELIUM; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; COMBINED MODALITY THERAPY; ENDOTHELIUM, VASCULAR; FEMALE; G1 PHASE; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; QUINAZOLINES; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036681995     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. The hazard of accelerated tumor clonogen repopulation during radiotherapy
2. Epidermal growth factor-related peptides and their receptors in human malignancies
3. The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells
4. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck
5. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas
6. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells
7. Radiation-induced proliferation of the human A 431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation
8. Modulation of molecular targets to enhance radiation
9. Development of inhibitors for protein tyrosine kinases
10. Studies leading to the identification of ZD1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
11. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
12. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers
13. Combination of ZD1839 ("Iressa"), an EGFR-TKI, and radiotherapy increases antitumor efficacy in a human colon cancer xenograft model
14. The effects of ZD1839 on cell signaling processes and its growth effects with radiation and chemotherapy in human non-small cell lung cancer cells in vitro
15. Modulation of radiation response and tumor-induced angiogenesis following EGFR inhibition by ZD1839 (Iressa) in human squamous cell carcinomas
16. Selective inhibition of the epidermal growth factor receptor tyrosine kinase (EGFR-TK) by ZD1839 ("Iressa") potentiates the antitumor effects of ionizing radiation
17. The selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ("Iressa") enhances radiation sensitivity of human tumor xenografts in nude mice
18. Potentiation of the antitumor effect of ionizing radiation by ZD1839 ("Iressa") in vitro and in vivo in A431 cells
19. Growth inhibition and radiosensitization of glioblastoma multiforme by the tyrosine kinase inhibitor ZD1839 (Iressa)
20. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
21. Combined Hoechst 33342 and merocyanine 540 staining to examine murine B cell cycle stage, viability and apoptosis
22. Different orders for acquisition of apoptotic characteristics by leukocytes
23. Extracellular matrix derived angiogenic factor(s) inhibit endothelial cell proliferation, enhance differentiation, and stimulate angiogenesis in vivo
24. Regulation of capillary formation by laminin and other components of the extracellular matrix
25. In vitro radiation resistance among cell lines established from patients with squamous cell carcinoma of the head and neck
26. Transforming growth factor-α-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation
27. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
28. Expression of growth factors and growth factor receptors in capillary hemangioblastoma
29. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology
30. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
31. Endothelial Apoptosis as the primary lesion initiating intestinal radiation damage in mice
32. Apoptosis and response to radiation: Implications for radiation therapy
33. Potential molecular targets for manipulating the radiation response
34. Radiation-induced apoptosis in sensitive and resistant cells isolated from a mouse lymphoma
35. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
36. Nuclear targeting of Bax during apoptosis in human colorectal cancer cells
37. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells
38. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
39. Epidermal growth factor receptor (HERI) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo
40. Targeting epidermal growth factor family members for treatment of breast cancer
41. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
42. Modulation of radiation response following epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics and tumor angiogenesis